Kimberly Byrd
Family · Ripley, TNNPI 1710172119
Payments from drug & device makers
Across 77 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$306
- Lilly USA, LLC$254
- GSK$243
- AbbVie$225
- Otsuka America Pharmaceutical, Inc.$78
- Johnson & Johnson$67
- plus $406 from 14 others
What the payments were for
- Food & beverage$1,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 14 | $306 |
| Lilly USA, LLC | 13 | $254 |
| GSK | 12 | $243 |
| AbbVie | 10 | $225 |
| Otsuka America Pharmaceutical, Inc. | 4 | $78 |
| Johnson & Johnson | 3 | $67 |
| Abbott | 3 | $65 |
| AstraZeneca | 3 | $54 |
| Neurocrine Biosciences, Inc. | 2 | $41 |
| Amgen | 2 | $30 |
| Seqirus USA Inc | 1 | $28 |
| Mylan Specialty L.p. | 2 | $26 |
| Insmed, Inc. | 1 | $23 |
| Exact Sciences | 1 | $22 |
| Boehringer Ingelheim | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Harmony Biosciences LLC | 1 | $20 |
| Sanofi | 1 | $20 |
| Mallinckrodt Hospital Products Inc. | 1 | $19 |
| Bayer | 1 | $18 |
How this compares
$1,579 in reported general payments places this provider in the 70th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 63 | $59,857 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $37,369 |
| EliquisApixaban | 29 | $27,646 |
| FarxigaDapagliflozin Propanediol | 32 | $25,723 |
| JanuviaSitagliptin Phosphate | 22 | $24,509 |
| MounjaroTirzepatide | 22 | $23,291 |
| Breo ElliptaFluticasone/Vilanterol | 41 | $19,707 |
| LinzessLinaclotide | 27 | $13,970 |
| Tresiba Flextouch U-100Insulin Degludec | 22 | $11,793 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,472 |
| GemtesaVibegron | 13 | $5,915 |
| Spiriva RespimatTiotropium Bromide | 11 | $5,454 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $5,168 |
| Novolog FlexpenInsulin Aspart | 14 | $3,739 |
| Ventolin HfaAlbuterol Sulfate | 42 | $3,716 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $306 | $59,85763 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $243 | $57,07686 claims |
| AstraZenecaFarxiga | $54 | $25,72332 claims |
| Lilly USA, LLCMounjaro | $254 | $23,29122 claims |
| AbbVieLinzess | $225 | $13,97027 claims |
| Boehringer IngelheimSpiriva Respimat | $21 | $5,45411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,706 family providers in Tennessee.
Other family in Ripley
- Stacy BrownMt Juliet$719K
- Dana WebberKnoxville$499K
- Brandy BiedermanHixson$448K
- Cynthia MillerMurfreesboro$384K
- Tamera ThoenerNashville$254K
- April SwonerHermitage$246K
- Jennifer WilliamsNashville$213K
- Chantil JeffreysGermantown$195K
- Laura PorchCordova$148K
- Lori LankfordNashville$148K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.